From Medscape Oncology

Coverage from the

San Antonio Breast Cancer Symposium (SABCS) 2021

December 07 - 10, 2021; Hybrid event: Virtual/Online & In Person in San Antonio, Texas

December 07 - 10, 2021 Hybrid event: Virtual/Online & In Person in San Antonio, Texas

SABCS 2021 Pyrotinib Boosts Survival in HER2+ Metastatic Breast Cancer Patients treated with pyrotinib plus capecitabine survived longer than those treated with lapatinib plus capecitabine in the PHOEBE trial.
Medscape Medical News, December 21, 2021
SABCS 2021 Therapy Switch Based on Mutation May Prolong PFS in Breast Cancer Patients with metastatic disease receiving aromatase inhibitor plus palbociclib and with a rising ESR1 mutation may benefit from early switch to fulvestrant plus palbociclib.
Medscape Medical News, December 14, 2021
SABCS 2021 No Benefit to Adding Palbociclib to Early Breast Cancer Therapy A phase 3 trial now confirms no benefit to adding palbociclib to endocrine therapy in early HR-positive, HER2-negative breast cancer.
Medscape Medical News, December 10, 2021

Conference News

SABCS 2021 Cost Not a Factor in RTx Type for Patients With Breast Cancer
Medscape Medical News, February 15, 2022
SABCS 2021 Pyrotinib Boosts Survival in HER2+ Metastatic Breast Cancer
Medscape Medical News, December 21, 2021
SABCS 2021 Cancer Risk Tied to Some Manufactured Foods
Medscape Medical News, December 17, 2021
SABCS 2021 Sacituzumab Govitecan Effective in Black mTNBC Patients
Medscape Medical News, December 17, 2021
SABCS 2021 Tumor Biology More Important Than Race in Predicting Treatment Response in Breast Cancer
Reuters Health Information, December 16, 2021
SABCS 2021 Most Oncologists Discuss Drug Side Effects, Open to Reduce Doses
Medscape Medical News, December 15, 2021
SABCS 2021 Therapy Switch Based on Mutation May Prolong PFS in Breast Cancer
Medscape Medical News, December 14, 2021
SABCS 2021 Vitamin D Counters Bone Density Loss With Aromatase Inhibitors
Medscape Medical News, December 14, 2021
SABCS 2021 Antibiotics Link to Triple-Negative Breast Cancer Mortality?
Medscape Medical News, December 14, 2021

SABCS 2021 1 in 7 Breast Cancers Are Overdiagnosed
Medscape Medical News, December 13, 2021
SABCS 2021 Ongoing HER2 Therapy May Cost an Additional $68,000 per Patient
Medscape Medical News, December 13, 2021
SABCS 2021 No Benefit to Adding Palbociclib to Early Breast Cancer Therapy
Medscape Medical News, December 10, 2021
SABCS 2021 Metformin Does Not Improve Outcomes in Early Breast Cancer
Medscape Medical News, December 9, 2021
SABCS 2021 In Metastatic Breast Cancer, Primary Resections on the Decline
Medscape Medical News, December 9, 2021
SABCS 2021 Should CDK4/6 Inhibitors Be Stopped in the Face of COVID-19?
Medscape Medical News, December 9, 2021
SABCS 2021 Black Women Most at Risk for Lymphedema After ALND
Medscape Medical News, December 7, 2021
SABCS 2021 Genomic Profiling Can Improve PFS in Metastatic Breast Cancer
Medscape Medical News, December 7, 2021
SABCS 2021 Novel SERD Reduces Risk of Death by 30% in HR+ Breast Cancer
Medscape Medical News, December 7, 2021

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Early Breast Cancer Highlights From SABCS 2021
Ann Partridge, MD, MPH
Advances in Metastatic Breast Cancer From SABCS 2021
Harold J. Burstein, MD, PhD

Popular News from SABCS 2020

RxPONDER: Even More Women May Forgo Chemo for Breast Cancer The first results from RxPONDER provide insight – and controversy – regarding the need for chemotherapy by women with node-positive, low-risk HR+, HER2- breast cancer.
Medscape Medical News, Dec 11, 2020
monarchE: Abemaciclib Reigns on in High-Risk Breast Cancer Extended follow-up from monarchE shows ongoing event-free survival benefits with abemaciclib + endocrine therapy in high-risk early breast cancer, although even longer follow-up is required, say experts.
Medscape Medical News, Dec 10, 2020
Pregnancy After Breast Cancer Doesn't Increase Recurrence Risk Among women who became pregnant, breast cancer survivors did not have higher odds of miscarriage or complications like preeclampsia, and their babies were not more likely to have congenital abnormalities.
Medscape Medical News, Dec 14, 2020

Previous Coverage